NA inhibitor, 3d | 1316304-24-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: NA inhibitor, 3d
• 英文别名: 2-[2-[(2-aminoacetyl)amino]-1,3-thiazol-4-yl]acetic acid
• CAS: 1316304-24-1
• 化学式: C₇H₉N₃O₃S
• 分子量: 215.233
• InChiKey: DVKGNKSSVPPZMN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  134
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  ethyl 2-(2-tert-butyloxycarbonylaminomethylcarbonylamino-1,3-thiazol-4-yl)acetate 在 盐酸 、 lithium hydroxide monohydrate 作用下， 以 1,4-二氧六环 、 水 、 乙酸乙酯 为溶剂， 反应 7.0h， 生成 NA inhibitor, 3d
  参考文献：
  名称：

  Design, synthesis, and biological activity of thiazole derivatives as novel influenza neuraminidase inhibitors

  摘要：

  A series of novel influenza neuraminidase (NA) inhibitors based on thiazole core were synthesized and evaluated for their ability to inhibit NA of influenza A virus (H3N2). All compounds were synthesized in good yields starting from commercially available 2-amino-4-thiazole-acetic ester using a suitable synthetic strategy. These compounds showed moderate inhibitory activity against influenza A NA. The most potent compound of this series is compound 4d (IC50 = 3.43 mu M), which is about 20-fold less potent than oseltamivir, and could be used to design novel influenza NA inhibitors that exhibit increased activity based on thiazole ring.

  DOI：

  10.3109/14756366.2010.534732

文献信息

• NOVEL COMPOUNDS
  申请人：Astra Pharmaceuticals Limited

  公开号：EP0996617A1

  公开（公告）日：2000-05-03
• 2,4-Dithi(oxo)-pyridin-5-yl compounds bearing a tricyclic substituent useful as P2 purinoceptor antagonists
  申请人：AstraZeneca AB

  公开号：EP0996617B1

  公开（公告）日：2002-01-09
• US6107297A
  申请人：——

  公开号：US6107297A

  公开（公告）日：2000-08-22
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES
  申请人：ASTRA PHARMACEUTICALS LTD.

  公开号：WO1999002501A1

  公开（公告）日：1999-01-21

  (EN) The invention relates to new pharmaceutically active compounds (I) which are P2-purinoceptor 7-transmembrane (TM) G-protein coupled receptor antagonists, compositions containing them and processes for their preparation, in which R2 is a group of formula (ii) or (iii).(FR) L'invention concerne de nouveaux composés (I) pharmaceutiquement actifs qui sont antagonistes du récepteur couplé aux protéines G transmembranaires 7 (TM) du purinorécepteur P2, des compositions les contenant et leurs procédés de préparation R2 est un groupe de la formule (ii) ou (iii).
• Design, synthesis, and biological activity of thiazole derivatives as novel influenza neuraminidase inhibitors
  作者：Yu Liu、Lei Zhang、Jianzhi Gong、Hao Fang、Ailin Liu、Guanhua Du、Wenfang Xu

  DOI：10.3109/14756366.2010.534732

  日期：2011.8.1

  A series of novel influenza neuraminidase (NA) inhibitors based on thiazole core were synthesized and evaluated for their ability to inhibit NA of influenza A virus (H3N2). All compounds were synthesized in good yields starting from commercially available 2-amino-4-thiazole-acetic ester using a suitable synthetic strategy. These compounds showed moderate inhibitory activity against influenza A NA. The most potent compound of this series is compound 4d (IC50 = 3.43 mu M), which is about 20-fold less potent than oseltamivir, and could be used to design novel influenza NA inhibitors that exhibit increased activity based on thiazole ring.